Eli Lilly and Co (HAM:LLY)
€ 1,039.4 +39.6 (+3.96%) Market Cap: 948.25 Bil Enterprise Value: 981.78 Bil PE Ratio: 42.92 PB Ratio: 34.60 GF Score: 98/100

Eli Lilly and Co at TD Cowen Healthcare Conference Transcript

Mar 02, 2026 / 08:10PM GMT
Release Date Price: €885 (+1.56%)
Steve Scala
Cowen and Company LLC - Analyst

Cowen's 46th Annual Healthcare Conference. And we are absolutely delighted to have Eli Lilly back at the conference again this year. Representing the company is Lucas Montarce, who is the CFO; as well as Mike Czapar, who is the Head of Investor Relations. So thank you so much for making the journey, and it's great to have you here.

Questions & Answers

Steve Scala;Lucas Montarce<
Cowen and Company LLC - Analyst

So much to talk about at Lilly, so many dynamics to dig into, so many details to explore. So we'll dig right into it. But should you have questions anywhere along the line, please just raise your hand, and we'll do our best to get your question answered. So probably the number one thing on people's mind is orforglipron, and we're all just holding our breaths waiting for its approval and launch. So maybe you can give us an update on how the review is going?

What stage you in? And what's your level of confidence that on April 10, we will get a letter of a positive nature?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot